Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloRx in Systemic Sclerosis
NCT05016804Phase 1Terminated
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Jul 2022
- Primary completion
- Nov 2025
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of AlloRx in systemic sclerosis (SSc), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Adverse Events at 4 years. Started Jul 2022; status: terminated.
02
Drugs
AlloRx
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT05016804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05016804.